published meta-analysis   sensitivity analysis   studies

corticosteroids in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsJamaati, 2021 1.19 [0.38; 3.72] Metcovid, 2020 0.92 [0.67; 1.28] Tang X, 2020 0.98 [0.93; 1.02] 0.98[0.93; 1.02]Jamaati, 2021, Metcovid, 2020, Tang X, 202030%529moderatenot evaluable deathsdetailed resultsCAPE-COVID, 2020 0.45 [0.20; 1.02] CODEX (Tomazini), 2020 0.97 [0.72; 1.31] DEXA-COVID19, 2020 2.00 [0.21; 18.87] Jamaati, 2021 1.19 [0.38; 3.72] Metcovid, 2020 0.92 [0.67; 1.28] RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92] Steroids-SARI, 2020 0.91 [0.29; 2.86] Tang X, 2020 0.98 [0.93; 1.02] 0.91[0.82; 1.01]CAPE-COVID, 2020, CODEX (Tomazini), 2020, DEXA-COVID19, 2020, Jamaati, 2021, Metcovid, 2020, RECOVERY dexamethasone, 2020, Steroids-SARI, 2020, Tang X, 2020838%7,467moderatenot evaluable clinical deteriorationdetailed resultsCODEX (Tomazini), 2020 0.66 [0.43; 1.02] Tang X, 2020 1.00 [0.13; 7.45] 0.67[0.44; 1.03]CODEX (Tomazini), 2020, Tang X, 202020%385moderatenot evaluable clinical improvementdetailed resultsTang X, 2020 1.04 [0.67; 1.62] 1.04[0.67; 1.62]Tang X, 202010%86NAnot evaluable clinical improvement (14-day)detailed resultsTang X, 2020 1.33 [0.57; 3.11] 1.33[0.57; 3.11]Tang X, 202010%86NAnot evaluable clinical improvement (time to event analysis only)detailed resultsTang X, 2020 1.04 [0.67; 1.62] 1.04[0.67; 1.62]Tang X, 202010%86NAnot evaluable death or ventilationdetailed resultsCAPE-COVID, 2020 0.71 [0.37; 1.35] RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01] 0.92[0.84; 1.00]CAPE-COVID, 2020, RECOVERY dexamethasone, 202020%5,567moderatenot evaluable hospital dischargedetailed resultsCAPE-COVID, 2020 1.67 [0.87; 3.19] RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17] 1.19[0.86; 1.64]CAPE-COVID, 2020, RECOVERY dexamethasone, 2020237%6,574moderatenot evaluable mechanical ventilationdetailed resultsCAPE-COVID, 2020 0.95 [0.44; 2.04] Jamaati, 2021 1.38 [0.45; 4.20] Metcovid, 2020 1.19 [0.56; 2.49] RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95] 0.82[0.67; 0.99]CAPE-COVID, 2020, Jamaati, 2021, Metcovid, 2020, RECOVERY dexamethasone, 202040%5,805moderatenot evaluable radiologic improvement (14-day)detailed resultsJamaati, 2021 4.89 [1.15; 20.79] 4.89[1.15; 20.79]Jamaati, 202110%50NAnot evaluable viral clearance detailed resultsTang X, 2020 1.78 [1.06; 3.00] 1.78[1.06; 3.00]Tang X, 202010%86NAnot evaluable viral clearance (time to event analysis only)detailed resultsTang X, 2020 1.78 [1.06; 3.00] 1.78[1.06; 3.00]Tang X, 202010%86NAnot evaluable ICU admissiondetailed resultsTang X, 2020 1.00 [0.13; 7.45] 1.00[0.13; 7.45]Tang X, 202010%86NAnot evaluable serious adverse eventsdetailed resultsCODEX (Tomazini), 2020 0.53 [0.17; 1.62] 0.53[0.17; 1.62]CODEX (Tomazini), 202010%299NAnot evaluable superinfectiondetailed resultsCAPE-COVID, 2020 0.81 [0.49; 1.34] Metcovid, 2020 0.98 [0.65; 1.47] 0.91[0.66; 1.25]CAPE-COVID, 2020, Metcovid, 202020%542moderatenot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-03-28 10:20 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 522,582,666,1149,1150,737,544,733 - roots T: 290